Supernus Pharmaceuticals
SUPN
289 hedge funds and large institutions have $1.81B invested in Supernus Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 119 increasing their positions, 78 reducing their positions, and 25 closing their positions.
68% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 25
53% more repeat investments, than reductions
Existing positions increased: 119 | Existing positions reduced: 78
8% more capital invested
Capital invested by funds: $1.67B → $1.81B (+$141M)
5% more funds holding
Funds holding: 274 → 289 (+15)
2.13% more ownership
Funds ownership: 99.31% → 101.44% (+2.1%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
45% less call options, than puts
Call options by funds: $8.25M | Put options by funds: $15.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NPIC
Neumeier Poma Investment Counsel
Carmel,
California
|
+$16.9M |
| 2 |
Two Sigma Investments
New York
|
+$13M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$12.1M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$9.19M |
| 5 |
Two Sigma Advisers
New York
|
+$8.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$50.1M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$8.95M |
| 3 |
Bank of New York Mellon
New York
|
-$6.18M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
-$5.96M |
| 5 |
Morgan Stanley
New York
|
-$5.58M |
SUPN Hedge Fund Activity: Q1 2019 in Review
289 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q1 2019, worth a combined $1.81B — up 8.4% from $1.67B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new SUPN positions and 25 closed out — a net gain of 17 holders — while 119 added to existing stakes and 78 trimmed.
The largest buyer was Neumeier Poma Investment Counsel, adding an estimated $16.9M. The largest seller was Fidelity Investments, cutting an estimated $50.1M.
- 289 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q1 2019, up from 274 in Q4 2018.
- Funds reported $1.81B of Supernus Pharmaceuticals stock for Q1 2019, up 8.4% quarter-over-quarter.
- 42 funds opened new Supernus Pharmaceuticals positions in Q1 2019 and 25 closed out, a net change of +17 holders.
- The largest Supernus Pharmaceuticals buyer in Q1 2019 was Neumeier Poma Investment Counsel, an estimated $16.9M added.
- The largest Supernus Pharmaceuticals seller in Q1 2019 was Fidelity Investments, an estimated $50.1M sold.
Based on aggregated 13F filings for Q1 2019.